125 related articles for article (PubMed ID: 36822993)
1. Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 2018.
Elgenidy A; Awad AK; Cheema HA; Shahid A; Kacimi SEO; Aly MG; Singla N; Afifi AM; Patel HD
Urol Oncol; 2023 Apr; 41(4):209.e11-209.e20. PubMed ID: 36822993
[TBL] [Abstract][Full Text] [Related]
2. Trends in cause of death among patients with renal cell carcinoma in the United States: a SEER-based study.
Zhan X; Chen T; Liu Y; Wan H; Liu X; Deng X; Fu B; Xiong J
BMC Public Health; 2023 Apr; 23(1):770. PubMed ID: 37101189
[TBL] [Abstract][Full Text] [Related]
3. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.
Kutikov A; Egleston BL; Wong YN; Uzzo RG
J Clin Oncol; 2010 Jan; 28(2):311-7. PubMed ID: 19933918
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of laterality in renal cell carcinoma: A population-based study from the surveillance, epidemiology, and end results (SEER) database.
Guo S; Yao K; He X; Wu S; Ye Y; Chen J; Wu CL
Cancer Med; 2019 Sep; 8(12):5629-5637. PubMed ID: 31407495
[TBL] [Abstract][Full Text] [Related]
5. Cause of Death During Renal Cell Carcinoma Survivorship: A Contemporary, Population-Based Analysis.
Yu DD; Chen WK; Wu CY; Wu WT; Xin X; Jiang YL; Li P; Zhang MH
Front Oncol; 2022; 12():864132. PubMed ID: 35719910
[TBL] [Abstract][Full Text] [Related]
6. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.
Saad AM; Gad MM; Al-Husseini MJ; Ruhban IA; Sonbol MB; Ho TH
Clin Genitourin Cancer; 2019 Feb; 17(1):46-57.e5. PubMed ID: 30391138
[TBL] [Abstract][Full Text] [Related]
7. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
8. Second malignant tumors and non-tumor causes of death for patients with localized and regional kidney cancer after diagnosis.
Yang L; Wu X; Zhou J; Song P; Liu Z; Chen J; Dong Q
Eur J Med Res; 2023 Jun; 28(1):206. PubMed ID: 37391781
[TBL] [Abstract][Full Text] [Related]
9. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
[TBL] [Abstract][Full Text] [Related]
10. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.
Patel HD; Gupta M; Joice GA; Srivastava A; Alam R; Allaf ME; Pierorazio PM
Eur Urol Oncol; 2019 Jul; 2(4):343-348. PubMed ID: 31277771
[TBL] [Abstract][Full Text] [Related]
11. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis.
Sun M; Abdollah F; Bianchi M; Trinh QD; Jeldres C; Tian Z; Shariat SF; Widmer H; Zorn K; Menon M; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2011 Dec; 60(6):1152-9. PubMed ID: 21868147
[TBL] [Abstract][Full Text] [Related]
12. Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study.
Wang Z; Wang J; Zhu Y; Liu C; Li X; Zeng X
Front Oncol; 2021; 11():604724. PubMed ID: 33777747
[TBL] [Abstract][Full Text] [Related]
13. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
14. High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid.
Wang S; Ge C
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10203-10215. PubMed ID: 37270459
[TBL] [Abstract][Full Text] [Related]
15. Predictors of locally advanced and metastatic disease in patients with small renal masses.
Kates M; Korets R; Sadeghi N; Pierorazio PM; McKiernan JM
BJU Int; 2012 May; 109(10):1463-7. PubMed ID: 21933329
[TBL] [Abstract][Full Text] [Related]
16. Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program.
Shuch B; Hofmann JN; Merino MJ; Nix JW; Vourganti S; Linehan WM; Schwartz K; Ruterbusch JJ; Colt JS; Purdue MP; Chow WH
Urol Oncol; 2014 Jan; 32(1):23.e9-13. PubMed ID: 23453468
[TBL] [Abstract][Full Text] [Related]
17. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for metachronous bilateral renal cell carcinoma: A surveillance, epidemiology, and end results analysis.
Syed JS; Nguyen KA; Holford TR; Hofmann JN; Shuch B
Cancer; 2019 Jan; 125(2):232-238. PubMed ID: 30561791
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing pediatric and adolescent renal cell carcinoma from other renal malignancies.
Syed JS; Nguyen KA; Wu CQ; Cost NG; Siddiqui MM; Hittelman AB; Shuch B
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27805307
[TBL] [Abstract][Full Text] [Related]
20. Tumor laterality in renal cancer as a predictor of survival in large patient cohorts: A STROBE compliant study.
Strauss A; Uhlig J; Lotz J; Trojan L; Uhlig A
Medicine (Baltimore); 2019 Apr; 98(17):e15346. PubMed ID: 31027111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
